Cited by 210Antifungal resistance and susceptibilityNosocomial Infections in ICUOcular Infections and Treatments

The DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.

Empirical Fluconazole versus Placebo for Intensive Care Unit Patients: A Randomized Trial

Schuster, Mindy G., Edwards, John E., Sobel, Jack D., Darouiche, Rabih O., Karchmer, Adolf W., Hadley, Susan, Slotman, Gus, Panzer, Helene, Biswas, Pinaki, Rex, John H.·2008·Annals of Internal Medicine

DOI 10.7326/0003-4819-149-2-200807150-00004

Open this paper in CoChat — free account

Abstract

BACKGROUND: Invasive infection with Candida species is an important cause of morbidity and mortality in intensive care unit (ICU) patients. Optimal preventive strategies have not been clearly defined. OBJECTIVE: To see whether empirical fluconazole improves clinical outcomes more than placebo in adult ICU patients at high risk for invasive candidiasis. DESIGN: Double-blind, placebo-controlled, randomized trial conducted from 1995 to 2000. SETTING: 26 ICUs in the United States. PATIENTS: 270 adult ICU patients with fever despite administration of broad-spectrum antibiotics. All had central venous catheters and an Acute Physiology and Chronic Health Evaluation II score greater than 16. INTERVENTION: Patients were randomly assigned to either intravenous fluconazole, 800 mg daily, or placebo for 2 weeks and were followed for 4 weeks thereafter. Two hundred forty-nine participants were available for outcome assessment. MEASUREMENTS: A composite primary outcome that defined success as all 4 of the following: resolution of fever; absence of invasive fungal infection; no discontinuation because of toxicity; and no need for a nonstudy, systemic antifungal medication (as assessed by a blinded oversight committee). RESULTS: Only 44 of 122 (36%) fluconazole recipients and 48 of 127 (38%) placebo recipients had a successful outcome (relative risk, 0.95 [95% CI, 0.69 to 1.32; P = 0.78]). The main reason for failure was lack of resolution of fever (51% for fluconazole and 57% for placebo). Documented invasive candidiasis occurred in 5% of fluconazole recipients and 9% of placebo recipients (relative risk, 0.57 [CI, 0.22 to 1.49]). Seven (5%) fluconazole recipients and 10 (7%) placebo recipients had adverse events resulting in discontinuation of the study drug. Discontinuation because of abnormal liver test results occurred in 3 (2%) fluconazole recipients and 5 (4%) placebo recipients. LIMITATIONS: Twenty-one randomly assigned patients were not included in the analysis because they either did not meet entry criteria or did not have postbaseline assessments. Fewer fungal infections than anticipated occurred in the control group. Confidence bounds were wide and did not exclude potentially important differences in outcomes between groups. CONCLUSION: In critically ill adults with risk factors for invasive candidiasis, empirical fluconazole did not clearly improve a composite outcome more than placebo.

Integrity signals

Registry

Crossref · 10.7326/0003-4819-149-2-200807150-00004

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Prevalence of Nosocomial Infection in Intensive Care Units in Europe
Vincent, J. (1995) · JAMA · doi:10.1001/jama.274.8.639 · Cited by 2,592
A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Self-citation
Increase in Candida krusei Infection among Patients with Bone Marrow Transplantation and Neutropenia Treated Prophylactically with Fluconazole
Wingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E., & Saral, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251803 · Cited by 937
Resistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 880
Self-citation
Hospital-Acquired Candidemia: The Attributable Mortality and Excess Length of Stay
Wey, S. B. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380120094019 · Cited by 831
Management of Fever in Patients with Cancer and Treatment-Induced Neutropenia
Wood, A. J. J., & Pizzo, P. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305063281808 · Cited by 831
Candida Colonization and Subsequent Infections in Critically III Surgical Patients
Pittet, D., Monod, M., Suter, P. M., Frenk, E., & Auckenthaler, R. (1994) · Annals of Surgery · doi:10.1097/00000658-199412000-00008 · Cited by 798
The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis
Zaoutis, T. E., Argon, J., Chu, J., Berlin, J. A., Walsh, T. J., & Feudtner, C. (2005) · Clinical Infectious Diseases · doi:10.1086/496922 · Cited by 784
The Epidemiology of Hematogenous Candidiasis Caused by Different Candida Species
Abi‐Said, D., Anaissie, E., Uzun, O., Raad, I., Pinzcowski, H., & Vartivarian, S. (1997) · Clinical Infectious Diseases · doi:10.1086/513663 · Cited by 755
1997 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever
Hughes, W. T., Armstrong, D., Bodey, G. P., Brown, A. E., Edwards, J. E., Feld, R. D., Pizzo, P. A., Rolston, K. V. I., Shenep, J. L., & Young, L. S. (1997) · Clinical Infectious Diseases · doi:10.1086/513764 · Cited by 664
Self-citation

Show all 28 references

Research works printed but not linked: 1

10.1001/jama.1995.03530080055041 · DOI

Sorted by citations

Items 101–200 of 210

Management of Antimicrobial Agents in Abdominal Organ Transplant Patients in Intensive Care Unit
Kaviani, A., İnce, D., & Axelrod, D. A. (2020) · Current Transplantation Reports · doi:10.1007/s40472-020-00268-0 · Cited by 18
Recognition and prevention of nosocomial invasive fungal infections in the intensive care unit
Smith, J. A., & Kauffman, C. A. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181e6cf25 · Cited by 18
Invasive Candida infections in the ICU
Eggimann, P., Barberini, L., Calandra, T., & Marchetti, O. (2012) · Mycoses · doi:10.1111/j.1439-0507.2011.02151.x · Cited by 17
Management of fungal infections in the intensive care unit: a survey of UK practice
Chalmers, C., & Bal, A. M. (2011) · British Journal of Anaesthesia · doi:10.1093/bja/aer089 · Cited by 16
Decreasing candidaemia rate in abdominal surgery patients after introduction of fluconazole prophylaxis*
Holzknecht, B. J., Thorup, J. M., Arendrup, M. C., Andersen, S. E., Steensen, M., Hesselfeldt, P., Nielsen, J., & Knudsen, J. D. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03422.x · Cited by 17
Antifungal Clinical Trials and Guidelines: What We Know and Do Not KnowPreprint
Pappas, P. G. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019745 · Cited by 17
Why Candida Sepsis Should Matter to ICU Physicians
Skrobik, Y. K., & Laverdière, M. (2013) · Critical Care Clinics · doi:10.1016/j.ccc.2013.06.007 · Cited by 16
Epidemiology of candidemia in lung transplant recipients and risk factors for candidemia in the early posttransplant period in the absence of universal antifungal prophylaxis
Marinelli, T. M., Pennington, K. M., Hamandi, B., Donahoe, L. L., Rotstein, C., Martinu, T., & Husain, S. (2022) · Transplant Infectious Disease · doi:10.1111/tid.13812 · Cited by 16
Defining standards of CARE for invasive fungal diseases in the ICU
Cuenca‐Estrella, M., Kett, D. H., & Wauters, J. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz038 · Cited by 16
Guías de práctica clínica para el manejo de la candidiasis: actualización del 2009, de la Infectious Diseases Society of America
Pappas, P. G., Kauffman, C. A., Andes, D. R., Benjamin, D. K., Calandra, T., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B. J., Ostrosky-Zeichner, L. L., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/598961 · Cited by 16
Self-citation
(1,3)-β-D-glucan-based diagnosis of invasive Candida infection versus culture-based diagnosis in patients with sepsis and with an increased risk of invasive Candida infection (CandiSep): study protocol for a randomized controlled trial
Bloos, F., Held, J., Schlattmann, P., Brillinger, N., Kurzai, O., Cornely, O. A., & Thomas-Rüddel, D. O. (2018) · Trials · doi:10.1186/s13063-018-2868-0 · Cited by 15
Treatment of invasive candidiasis: between guidelines and daily clinical practice
Tagliaferri, E., & Menichetti, F. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1029916 · Cited by 14
Clinical Aspects of Invasive Candidiasis in Critically Ill Patients
Pennisi, M. A., & Antonelli, M. M. (2009) · Drugs · doi:10.2165/11315590-000000000-00000 · Cited by 15
Tolerability of pulsed high-dose L-AmB as pre-emptive therapy in patients at high risk for intra-abdominal candidiasis: A phase 2 study (LAMBDA study)
Rinaldi, M., Bartoletti, M., Bonazzetti, C., Caroccia, N., Gatti, M., Tazza, B., Horna, C. S., Giannella, M., & Viale, P. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106998 · Cited by 13
Métodos diagnósticos en candidemia: una revisión sistemática de la literatura con meta-análisis
Cortés, J. A., Mejía, A. C., Luis Eduardo Cediel, T., & Castillo, J. S. (2011) · Revista chilena de infectología · doi:10.4067/s0716-10182011000600006 · Cited by 13
Weekly high-dose liposomal amphotericin B (L-AmB) in critically ill septic patients with multiple Candida colonization: The AmBiDex study
Azoulay, É., Timsit, J., Lautrette, A., Legriel, S., Max, A., Ruckly, S., Misset, B., Cohen, Y., & Wolff, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177093 · Cited by 13
Significant publications on infectious diseases pharmacotherapy in 2008
Kuper, K. M., Hirsch, E. B., & Tam, V. H. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp090099 · Cited by 13
A prospective analysis of invasive candidiasis following cardiac surgery: Severity markers are predictive
Forstner, C., Lassnigg, A. M., Tobudic, S., Schiferer, A., Fischer, H., Graninger, W., Steinlechner, B., Frantal, S., & Presterl, E. (2013) · Journal of Infection · doi:10.1016/j.jinf.2013.02.003 · Cited by 12
Candida: What Should Clinicians and Scientists Be Talking About?
Spellberg, B. J., Marr, K. A., & Filler, S. G. (2014) · ASM Press eBooks · doi:10.1128/9781555817176.ch1 · Cited by 13
Exploiting antifungal immunity in the clinical context
Lionakis, M. S. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101752 · Cited by 12
Guidelines for the treatment of severe sepsis and septic shock - management of the infectious agent - source control and antimicrobial treatment.
Salomão, R., Diament, D., Rigato, O., Gomes, B., Silva, E., Carvalho, N. B., & Machado, F. R. (2011) · PubMed · Cited by 11
Untargeted Antifungal Treatment Strategies for Invasive Candidiasis in Non-neutropenic Critically Ill Patients: Current Evidence and Insights
Cortegiani, A., Russotto, V., Raineri, S. M., Gregoretti, C., Rosa, F. G. D., & Giarratano, A. (2017) · Current Fungal Infection Reports · doi:10.1007/s12281-017-0288-3 · Cited by 11
Major publications in the critical care pharmacotherapy literature: January–December 2016
Horner, D., Altshuler, D., Droege, C., Feih, J. T., Ferguson, K., Fiorenza, M. A., Greathouse, K. M., Hamilton, L. A., Pfaff, C., Roller, L. K., et al. (2017) · Journal of Critical Care · doi:10.1016/j.jcrc.2017.09.178 · Cited by 11
Systemic Candidiasis: Candidemia and Deep-Organ Infections
Clancy, C. J., & Nguyen, M. H. (2014) · ASM Press eBooks · doi:10.1128/9781555817176.ch27 · Cited by 12
Intensive care unit-related fluconazole use in Spain and Germany: patient characteristics and outcomes of a prospective multicenter longitudinal observational study
Kaskel, P., Wissing, Ballús, J., Bingold, T. M., Nocea, Krobot, Kumar, & Mavros, P. (2013) · Infection and Drug Resistance · doi:10.2147/idr.s38945 · Cited by 10
Antifungal Stewardship: an Emerging Practice in Antimicrobial Stewardship
Andruszko, B., & Ashley, E. D. (2016) · Current Clinical Microbiology Reports · doi:10.1007/s40588-016-0039-1 · Cited by 11
Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use
Nett, J. E., & Andes, D. R. (2014) · ASM Press eBooks · doi:10.1128/9781555817176.ch22 · Cited by 10
Empirical Antifungal Therapy in Critically Ill Patients With Sepsis
Siddharthan, T., Karakousis, P. C., & Checkley, W. (2016) · JAMA · doi:10.1001/jama.2016.13801 · Cited by 10
Update: invasive Pilzinfektionen: Diagnose und Therapie in der operativen Intensivmedizin
Lichtenstern, C., Swoboda, S., Hirschburger, M., Domann, E., Hoppe‐Tichy, T., Winkler, M., Lass‐Flörl, C., & Weigand, M. A. (2010) · Der Anaesthesist · Cited by 9
Invasive candidiasis in critically ill patients: does progressing knowledge improve clinical management and outcome?
Marchetti, O., Eggimann, P., & Calandra, T. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e2629 · Cited by 9
Update: invasive Pilzinfektionen
Lichtenstern, C., Swoboda, S., Hirschburger, M., Domann, E., Hoppe‐Tichy, T., Winkler, M., Lass‐Flörl, C., & Weigand, M. A. (2010) · Der Anaesthesist · doi:10.1007/s00101-009-1655-4 · Cited by 11
Should we Administer Antifungal Drugs Before the Diagnosis of Invasive Fungal Infection in Non-Neutropenic Critically Ill Patients?
Cortegiani, A., Russotto, V., Raineri, S. M., Gregoretti, C., & Giarratano, A. (2017) · Türk anesteziyoloji ve reanimasyon derneği dergisi · doi:10.5152/tjar.2016.0010 · Cited by 9
Initial therapeutic strategy of invasive candidiasis for intensive care unit patients: a retrospective analysis from the China-SCAN study
on behalf of the China-SCAN Team, Cui, N., Wang, H., Su, L., Qiu, H., Li, R., & Liu, D. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2207-1 · Cited by 8
Choosing Optimal Antifungal Agents To Prevent Fungal Infections in Nonneutropenic Critically Ill Patients: Trial Sequential Analysis, Network Meta-analysis, and Pharmacoeconomic Analysis
Wang, Y., Xie, J., Xing, Y., Chen, L., Li, Y., Meng, T., Dong, W., Wang, X., & Dong, Y. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00620-17 · Cited by 8
Risk factors for noncatheter-related Candida bloodstream infections in intensive care units: A multicenter case-control study
Arslan, F., Çaşkurlu, H., Sarı, S., Dal, H. C., Turan, S., Şengel, B. E., Gül, F., Yeşilbağ, Z., Eren, G. A., Temel, Ş., et al. (2018) · Medical Mycology · doi:10.1093/mmy/myy127 · Cited by 8
Update in Critical Care 2008
Fowler, R., Adhikari, N. K. J., Scales, D. C., Lee, W. L., & Rubenfeld, G. D. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200902-0207up · Cited by 8
Empirical Therapy for Invasive Candidiasis in Critically Ill Patients
Bartalucci, C., Giacobbe, D. R., Vena, A., & Bassetti, M. (2024) · Current Fungal Infection Reports · doi:10.1007/s12281-024-00489-1 · Cited by 8
Controversies in Candida management
Zakhem, A. E., Saad, H. A., Tayyar, R., & Kanj, S. S. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.10.008 · Cited by 7
Clinical Syndromes: Candida and Candidosis
Ruhnke, M. (2018) · Springer eBooks · doi:10.1007/978-3-319-92300-0_4 · Cited by 7
Management of Infections with Drug-Resistant Organisms in Critical Care
Trevino, S. E., & Kollef, M. H. (2015) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2015.05.007 · Cited by 7
Factors predicting prolonged empirical antifungal treatment in critically ill patients
Zein, M., Parmentier-Decrucq, E., Kalaoun, A., Bouton, O., Wallyn, F., Baranzelli, A., Manser, D. E., Sendid, B., & Nseir, S. (2014) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-13-11 · Cited by 6
Antifungal use in intensive care units: another uncertainty that highlights the need for precision medicine
Moghnieh, R., Kanafani, Z. A., & Kanj, S. S. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.12.97 · Cited by 6
The EMPIRICUS trial—the final nail in the coffin of empirical antifungal therapy in the intensive care unit?
Osthoff, M. F., Khanna, N., & Siegemund, M. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.02.78 · Cited by 6
Does the current treatment of invasive fungal infection need to be reviewed?
Martín‐Peña, A., Aguilar‐Guisado, M., & Cisneros, J. M. (2013) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2013.02.008 · Cited by 5
Issues in the design and interpretation of antifungal drug trials in the critically ill
Ostrosky-Zeichner, L. L. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328331fc5f · Cited by 5
Evaluating antimicrobial stewardship strategies in candidemia: a novel desirability of outcome ranking (DOOR) analysis comparing blood culture versus T2Candida diagnostic approaches
Caniff, K. E., Musawa, M. A., Judd, C., Shupp, M., Veve, M. P., Alangaden, G. J., Claeys, K. C., Scipione, M. R., Walsh, T. J., & Rybak, M. J. (2025) · Journal of Clinical Microbiology · doi:10.1128/jcm.00043-25 · Cited by 4
Management of invasive candidiasis in nonneutropenic ICU patients
Weiss, E., & Timsit, J. (2014) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936114562586 · Cited by 5
Early Empirical Anidulafungin Reduces the Prevalence of Invasive Candidiasis in Critically Ill Patients: A Case-control Study
Hasan, M. J., Neelotpol, S., & Rabbani, R. (2022) · The Journal of Critical Care Medicine · doi:10.2478/jccm-2022-0006 · Cited by 4
Management of invasive fungal infections in the pediatric intensive care unit
Fisher, B. T., Zaoutis, T. E., & Chiotos, K. (2015) · Journal of Pediatric Intensive Care · doi:10.3233/pic-14108 · Cited by 4
Empiric/pre-emptive anti-Candida therapy in non-neutropenic ICU patients
Timsit, J., Chemam, S., & Bailly, S. (2015) · F1000Prime Reports · doi:10.12703/p7-21 · Cited by 4
Traitements antifongiques en réanimation au cours des infections fongiques invasives documentées ou suspectées
Massanet, P. L., Jung, B., Molinari, N., Villiet, M., Moulaire, V., Roch-Torreilles, I., Jaber, S., Reynes, J., & Corne, P. (2014) · Annales Françaises d Anesthésie et de Réanimation · doi:10.1016/j.annfar.2014.02.016 · Cited by 4
Candida Prophylaxis and Treatment in Critically Ill Patients after Abdominal Surgery: A Survey of Practice
Einav, S., Raveh, D., Lachish, T., Baumstarck, K., Martin, C., Martín‐Loeches, I., & Léone, M. (2019) · Surgical Infections · doi:10.1089/sur.2018.267 · Cited by 4
Mucocutaneous and Deeply Invasive Candidiasis
Shoham, S., Nucci, M., & Walsh, T. J. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7020-3935-5.00088-4 · Cited by 4
What is the role of empirical treatment for suspected invasive candidiasis in non-neutropenic non transplanted patients in the intensive care unit?—Empiricus strikes back!
Bretonnière, C., Lakhal, K., Lepoivre, T., Boutoille, D., & Morio, F. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.12.99 · Cited by 4
Comparative study of the effect of Eucalyptus extract on Candida albicans and human pathogenic bacteria
Dehbashi, Z., Forghani, F., Sabbagh, S. K., & Saeidi, S. (2017) · Journal of Herbal Drugs: International Journal on Medicinal Herbs · doi:10.18869/jhd.2017.93 · Cited by 4
Diagnosis and Management of Invasive Candida Infections in Critically Ill Patients
Zakhem, A. E., Istambouli, R., Jabbour, J.-F., Hindy, J.-R., Gharamti, A. A., & Kanj, S. S. (2022) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0041-1741009 · Cited by 3
Evaluation of an Antifungal Stewardship Initiative Targeting Micafungin at an Academic Medical Center
Keck, J. M., Cretella, D. A., Stover, K. R., Wagner, J. L., Barber, K. E., Jhaveri, T. A., Vijayvargiya, P., Garrigos, Z. E., & Wingler, M. J. B. (2023) · Antibiotics · doi:10.3390/antibiotics12020193 · Cited by 3
Nouveaux marqueurs pour le diagnostic de la maladie fongique invasive
Poissy, J., Parmentier-Decrucq, E., Sendid, B., Mathieu, D., & Poulain, D. (2014) · Réanimation · doi:10.1007/s13546-014-0866-4 · Cited by 3
Fungal Infections in Cancer Patients
Granwehr, B. P., & Kontoyiannis, D. P. (2021) · Springer eBooks · doi:10.1007/978-3-319-74698-2_121-2 · Cited by 3
Azoles: back to the future
Perfect, J. R. (2011) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000399605.75891.fc · Cited by 3
Candidemia and non-candidemia related septic shock: are there differences between them?
Kollef, M. H., Paiva, J.-A., & Charles, P. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3332-6 · Cited by 3
Antifungal treatment strategies in intensive care unit patients
Bartalucci, C., Mezzogori, L., Schiavoni, R., Vena, A. R., Giacobbe, D. R., & Bassetti, M. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70177 · Cited by 3
IgG1 anti-cell wall and IgG2 anti-phosphopeptidomannan antibodies in the diagnosis of invasive candidiasis and heavyCandidacolonization
Mattsby‐Baltzer, I., Pinel, C., Marcos, J. Y., Kondori, N., Potton, L., Thiébaut, A., Pelloux, H., & Cornet, M. (2015) · Medical Mycology · doi:10.1093/mmy/myv037 · Cited by 2
Indication des traitements antifongiques (hors hématologie). Que montrent les données ?
Huette, P., & Dupont, H. (2019) · Anesthésie & Réanimation · doi:10.1016/j.anrea.2019.03.004 · Cited by 2
Candida Sepsis: a New Entity?
Caeiro, J. P., & Riera, F. O. (2014) · Current Fungal Infection Reports · doi:10.1007/s12281-013-0171-9 · Cited by 3
Shock Syndromes Related to Sepsis
Russell, J. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00108-1 · Cited by 2
Antifungal drugs
Schrey, D., Walsh, T. J., & Groll, A. H. (2011) · Side effects of drugs annual · doi:10.1016/b978-0-444-53741-6.00027-1 · Cited by 2
Effect of empirical antifungal treatment on mortality in non-neutropenic critically ill patients: a propensity-matched retrospective cohort study
Tang, Y., Hu, W., Jiang, S., Xie, M., Zhu, W., Zhang, L., Sha, J., Wang, T., Ding, M., Zeng, J., et al. (2022) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-022-04507-3 · Cited by 2
Azoles
Andes, D. R., & Dismukes, W. E. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6640-7_5 · Cited by 3
Update on invasive opportunistic mycoses: Clinical trials review, 2008–2009
Groll, A. H. (2009) · Current Infectious Disease Reports · doi:10.1007/s11908-009-0060-0 · Cited by 2
The Answer Is In: Fluconazole Prophylaxis Is Not Beneficial for Intensive Care Unit Patients without Neutropenia
Fekete, T. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-2-200807150-00011 · Cited by 2
Invasive Candidiasis in the Intensive Care Unit
Krishnan, S., & Ostrosky-Zeichner, L. L. (2010) · Hospital Practice · doi:10.3810/hp.2010.04.298 · Cited by 1
Should Preventive Antifungal Treatment Be Given to Patients With Abdominal Contamination in the Intensive Care Unit?
ÖNDER, K. D., & Keski̇n, A. S. (2023) · Cureus · doi:10.7759/cureus.35071 · Cited by 1
Antibiotic Considerations in the Critically Ill
Gillett, E. M., Dube, K. M., & Rhee, C. (2026) · Critical Care Clinics · doi:10.1016/j.ccc.2026.01.003 · Cited by 1
Brazilian guidelines for the diagnosis and treatment of candidemia and invasive candidiasis in adults and children
Colombo, A. L., Magri, M. M. C., Carlesse, F. A. D. M. C., Falci, D. R., Garnica, M., Santos, D. W. D. C. L., Queiroz‐Telles, F., & Pasqualotto, A. C. (2026) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2026.105946 · Cited by 1
Early Recognition of Invasive Candidiasis in the ICU
Charles, P., Bruyère, R., & Dalle, F. (2012) · Springer eBooks · doi:10.1007/978-3-642-25716-2_29 · Cited by 1
1–3 β-D-glucan: From Diagnosis to Prognosis
Richards, E. P., Mohammadi, S., & Forrest, G. N. (2012) · Current Fungal Infection Reports · doi:10.1007/s12281-012-0118-6 · Cited by 1
Invasive Candidiasis in the Intensive Care Setting
GASPERI, A. D., Cozzi, P., & Colombo, S. (2013) · Springer eBooks · doi:10.1007/978-88-470-5529-2_13 · Cited by 1
Antimicrobial activity and immunological side effects of different antibiotics.
Dorić, M., Abram, M., & Rukavina, T. (1993) · PubMed · Cited by 1
Fungal Infections in Cancer Patients
Granwehr, B. P., Sipsas, N. V., & Kontoyiannis, D. P. (2019) · Springer eBooks · doi:10.1007/978-3-319-74588-6_121 · Cited by 1
Invasive Candidiasis
Traboulsi, R. S. (2009) · CRC Press eBooks · doi:10.3109/9780849387869-17 · Cited by 1
Candida Infections in Hematopoietic and Solid Organ Transplant Recipients
Freifeld, A. G., & Kauffman, C. A. (2019) · Springer eBooks · doi:10.1007/978-1-4939-9034-4_32 · Cited by 1
Tolerability of pulse high dose L-AmB as pre-emptive therapy in patients at high risk for intra- abdominal candidiasis: a phase 2 study (LAMBDA Study)Preprint
Rinaldi, M., Bartoletti, M., Bonazzetti, C., Caroccia, N., Gatti, M., Tazza, B., Horna, C. S., Giannella, M., & Viale, P. (2023) · Research Square · doi:10.21203/rs.3.rs-2943124/v1 · Cited by 1
Indications des antifongiques systémiques, spécialité par spécialité
de Guibert, S., Gandemer, V., Belleguic, C., Revest, M., Camus, C., Caulet-Maugendre, S., Cardiet, I., Faucheux, M., Meunier, C. M., & Gangneux, J. (2010) · HAL · doi:10.1684/met.2010.0282
Empirical Use of Fluconazole in Critically Ill Patients: Good Study, but What Was the Hold-up?
Shelburne, S. A. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-1-200901060-00016
Can fungal biomarkers be used to improve antifungal therapy in the intensive care unit?
Ostrosky‐Zeichner, L. (2009) · Current Fungal Infection Reports · doi:10.1007/s12281-009-0019-5
Medical Mycology for the Hospital Epidemiologist
Barron, M. A. (2012) · Current Fungal Infection Reports · doi:10.1007/s12281-011-0077-3
Empirical Use of Fluconazole in Critically Ill Patients: Good Study, but What Was the Hold-up?
Lee, D. H. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-1-200901060-00017
Appropriateness and cost-effectiveness in the treatment of invasive candidiasis in Internal Medicine Wards
Tagliaferri, E., & Menichetti, F. (2014) · Italian Journal of Medicine · doi:10.4081/itjm.2014.536
Empirical Fluconazole Doesn’t Help
Baum, S. G. (2008) · Journal watch · doi:10.1056/id200808060000002
Micafungin Use
Grant, M. D., Fekete, T., & Axelrod, P. I. (2013) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0b013e318297d5d5
Selection of Antibiotics in Critical Care
Ahuja, D., Britt, B. B., & Bryan, C. S. (2009) · Infectious disease and therapy · doi:10.3109/9781420080049.026
Prostate Cancer and Other Primary Malignancies
Schaff, M. S., & Mydlo, J. H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800077-9.00008-6
Pulmonary and Critical Care Updates Update in Critical Care 2008
Fowler, R., Adhikari, N. K. J., Scales, D. C., Lee, W. L., & Rubenfeld, G. D. (2009)
Update: invasive Pilzinfektionen Diagnose und Therapie in der operativen Intensivmedizin
Anaesthesiologie, K. F., Heidelberg, U., & Briegel, J. (2010)
What Is the Most Recent Evidence on the Prevention and Early Treatment of Invasive Fungal Infections in Nonneutropenic Critically Ill Patients?
Cortegiani, A., Russotto, V., Iozzo, P., Raineri, S. M., & Giarratano, A. (2017) · Archives of Clinical Infectious Diseases · doi:10.5812/archcid.12414
THE TRANSMUTED GENERALIZED LINDLEY DISTRIBUTION: PROPERTIES AND AN APPLICATION TO A DATA SET ON TIME-UP-TO-CURE OF PATIENTS TREATED WITH A TRIAZOLE ANTIFUNGAL DRUG IN AN INTENSIVE CARE UNIT
Louzada, F., Elbatal, I., & Granzotto, D. C. T. (2018) · Brazilian Journal of Biometrics · doi:10.28951/rbb.v36i2.207
Treatment of fungal infections in adult pulmonary and critical care patients
общества, Т., грибковой, Л., инфекции, У., пациентов, В., & терапии, И. (2014)
New Developments in Diagnostics and Management of Invasive Candidiasis
Krishnan, S., & Ostrosky‐Zeichner, L. (2014) · ASM Press eBooks · doi:10.1128/9781555817176.ch28
Fungal Infections in Cancer Patients
Granwehr, B. P., Sipsas, N. V., & Kontoyiannis, D. P. (2019) · Springer eBooks · doi:10.1007/978-3-319-74698-2_121-1

Authors: Schuster, M. G., Edwards, J. E., Sobel, J. D., Darouiche, R. O., Karchmer, A. W., Hadley, S., Slotman, G., Panzer, H., Biswas, P., & Rex, J. H.
Affiliations: Tufts Medical Center (US)
Tufts University (US)
AstraZeneca (United Kingdom) (GB)
ORCID: Schuster, Mindy G.
Edwards, John E.
Karchmer, Adolf W.
Hadley, Susan
Biswas, Pinaki
Rex, John H.
Venue: Annals of Internal Medicine
Publisher: American College of Physicians
Published: 2008-07-15
Volume: 149
Issue: 2
Pages: 83-90
ISSN: 0003-4819 (ISSN-L)
1539-3704
DOI: 10.7326/0003-4819-149-2-200807150-00004
OpenAlex: W2041927838
Semantic Scholar: 7f6c28e24e62a031b9fbd07664f827cb67f8e714
Cited by: 210
References: 28
Citations by year: 2026: 7 · 2025: 4 · 2024: 3 · 2023: 6 · 2022: 5 · 2021: 3 · 2020: 5 · 2019: 14 · 2018: 7 · 2017: 15 · 2016: 12 · 2015: 14 · 2014: 20 · 2013: 11 · 2012: 16
FWCI: 14.30
Type: journal article
Language: en
Open access: closed
Licence: www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations: Annals of Internal Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Pfizer
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Nosocomial Infections in ICU
Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
Keywords: invasive candidiasis, fluconazole, intensive care unit patients, critically ill adults, central venous catheters, APACHE II score, antifungal toxicity, liver function tests, composite endpoints, treatment discontinuation, ICU length of stay, cost-effectiveness
MeSH terms: Adult, Aged, Antifungal Agents, Candidiasis, Critical Care, Cross Infection, Double-Blind Method, Female, Follow-Up Studies, Humans, Intensive Care Units, Male, Middle Aged, Risk Factors, Fluconazole, Fungemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Empirical Fluconazole versus Placebo for Intensive Care Unit Patients: A Randomized Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks